Stem-Cell Transplantation for High-Risk Breast Cancer

Publisher Website
Google Scholar
Abstract
The controversy over the question of whether to use high-dose chemotherapy and autologous hematopoietic stem-cell transplantation in women with high-risk breast cancer has persisted for more than a decade.1 It has never been more clearly highlighted than it is in the articles by Rodenhuis2 and Tallman3 and their colleagues in this issue of the Journal. Rodenhuis et al. conclude that “high-dose alkylating therapy improves relapse-free survival among patients with stage II or III breast cancer and 10 or more positive axillary lymph nodes,” whereas Tallman et al. conclude that “the addition of high-dose chemotherapy and autologous hematopoietic stem-cell transplantation . . .